| scholarly article | Q13442814 |
| P356 | DOI | 10.3109/13506129.2011.627069 |
| P698 | PubMed publication ID | 22070520 |
| P50 | author | Alessandra Barassi | Q57314389 |
| Francesca Lavatelli | Q80557915 | ||
| Giovanni Palladini | Q37839091 | ||
| Giampaolo Merlini | Q37839101 | ||
| Paolo Milani | Q44254925 | ||
| Laura Obici | Q56426698 | ||
| Stefano Perlini | Q57005375 | ||
| P2093 | author name string | Riccardo Albertini | |
| Andrea Foli | |||
| Paola Russo | |||
| Gian Vico Melzi d'Eril | |||
| Remigio Moratti | |||
| Gabriele Sarais | |||
| Simona Casarini | |||
| P2860 | cites work | Midwall mechanics are improved after regression of hypertensive left ventricular hypertrophy and normalization of chamber geometry. | Q31825779 |
| Identification of an Adrenomedullin precursor fragment in plasma of sepsis patients | Q33206500 | ||
| Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis, Tours, France, 18-22 April 2004. | Q34437074 | ||
| Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate | Q34557258 | ||
| Systemic cardiac amyloidoses: disease profiles and clinical courses of the 3 main types. | Q35002777 | ||
| Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis | Q35886289 | ||
| Clinical aspects of systemic amyloid diseases. | Q36274065 | ||
| Adrenomedullin: molecular mechanisms and its role in cardiac disease | Q36438893 | ||
| Dangerous small B-cell clones. | Q36516158 | ||
| Survival in patients with primary systemic amyloidosis and raised serum cardiac troponins | Q44022591 | ||
| Mid-region pro-hormone markers for diagnosis and prognosis in acute dyspnea: results from the BACH (Biomarkers in Acute Heart Failure) trial | Q44360648 | ||
| Adrenomedullin: a novel hypotensive peptide isolated from human pheochromocytoma | Q45345831 | ||
| Measurement of midregional proadrenomedullin in plasma with an immunoluminometric assay | Q46650090 | ||
| Circulating amyloidogenic free light chains and serum N-terminal natriuretic peptide type B decrease simultaneously in association with improvement of survival in AL. | Q46909999 | ||
| The combination of high-sensitivity cardiac troponin T (hs-cTnT) at presentation and changes in N-terminal natriuretic peptide type B (NT-proBNP) after chemotherapy best predicts survival in AL amyloidosis | Q48121592 | ||
| Prognostic value of midregional pro-adrenomedullin in patients with acute myocardial infarction: the LAMP (Leicester Acute Myocardial Infarction Peptide) study | Q48211868 | ||
| Comparative evaluation of B-type natriuretic peptide, mid-regional pro-A-type natriuretic peptide, mid-regional pro-adrenomedullin, and Copeptin to predict 1-year mortality in patients with acute destabilized heart failure | Q48252671 | ||
| Serum N-terminal pro-brain natriuretic peptide is a sensitive marker of myocardial dysfunction in AL amyloidosis | Q48323509 | ||
| Adrenomedullin in sinusoidal endothelial cells play protective roles against cold injury of liver. | Q54442905 | ||
| P433 | issue | 4 | |
| P921 | main subject | AL amyloidosis | Q4652470 |
| P304 | page(s) | 216-221 | |
| P577 | publication date | 2011-11-09 | |
| P1433 | published in | Amyloid | Q4749545 |
| P1476 | title | Midregional proadrenomedullin (MR-proADM) is a powerful predictor of early death in AL amyloidosis | |
| P478 | volume | 18 |
| Q57177490 | Current and future circulating biomarkers for cardiac amyloidosis |
| Q44497204 | Effects of acute exercise and xanthine oxidase inhibition on novel cardiovascular biomarkers |
| Q34091229 | Increased serum free light chains precede the presentation of immunoglobulin light chain amyloidosis |
| Q39272596 | Light-chain cardiac amyloidosis: strategies to promote early diagnosis and cardiac response |
| Q39024208 | New and Evolving Concepts Regarding the Prognosis and Treatment of Cardiac Amyloidosis |
| Q38100987 | New and emerging biomarkers in left ventricular systolic dysfunction--insight into dilated cardiomyopathy |
| Q47561519 | New concepts in the treatment and diagnosis of amyloidosis |
| Q28069975 | Rationale, application and clinical qualification for NT-proBNP as a surrogate end point in pivotal clinical trials in patients with AL amyloidosis |
| Q54365449 | Serum copeptin and midregion proadrenomedullin (MR-proADM) after an ultramarathon. |
| Q91739667 | Systemic amyloidosis: moving into the spotlight |
| Q38829923 | Systemic amyloidosis: novel therapies and role of biomarkers |
Search more.